A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03472053|
Recruitment Status : Recruiting
First Posted : March 21, 2018
Last Update Posted : July 9, 2018
|Condition or disease||Intervention/treatment||Phase|
|Non Small Cell Lung Cancer Stage IIIB||Drug: BIO-11006 plus standard of care Drug: Standard of Care||Phase 2|
This randomized, open label, multicenter Phase 2 study is to evaluate safety and efficacy of BIO-11006 in Stage IIIB Non Small Cell Lung cancer (NSCLC) patients who are not candidates for curative surgery, radiation, or immunotherapy and who are also receiving Pemetrexed and Carboplatin as standard of care (SOC). This study will be conducted at ten clinical centers in India under an IND from US-FDA and an IND from Indian FDA.
This is a parallel 2- Arm study in which a total of 60 patients will be randomized. One Arm of 30 subjects will receive aerosolized 125mg BIO-11006 BID using Pari eFlow nebulizer in conjunction with SOC chemotherapy (Pemetrexed plus Carboplatin). A second Arm of 30 subjects will receive only SOC chemotherapy (Pemetrexed plus Carboplatin). The treatment period will be three months and nine months survival follow up period (every three months).
Primary efficacy endpoint will be Progression-free survival (PFS) in patients who receive BIO-11006 plus SOC compared to those who receive SOC alone. The secondary efficacy endpoints will include: a. Response rate at three months (4 cycles) per RECIST V1.1; (b) overall survival; and (c) patient body weight maintenance.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Patients will be randomized in 1:1 ratio to either BIO-11006 plus Standard of Care (intervention) or Standard of Care (Pemetrexed plus Carboplatin) (intervention).|
|Masking:||None (Open Label)|
|Official Title:||A Randomized Study of the Safety and Efficacy of BIO-11006 in Treatment of Advanced Non-Small Cell Lung Cancer in Patients Who Are Not Candidates for Curative Surgery and/or Radiation and Who Are Receiving Pemetrexed and Carboplatin|
|Actual Study Start Date :||February 1, 2018|
|Estimated Primary Completion Date :||January 31, 2019|
|Estimated Study Completion Date :||June 30, 2019|
Experimental: BIO-11006 plus standard of care
Aerosolized BIO-11006 (125mg BID) plus standard of care (Pemetrexed plus Carboplatin) is administered for three months.
Drug: BIO-11006 plus standard of care
BIO-11006 is administered 125mg BID plus standard of care.
Other Name: Active drug plus standard of care
Experimental: Standard of Care
Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's Formula) is administered every three weeks for three months.
Drug: Standard of Care
Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's formula) are administered every three weeks for three months.
Other Name: Active comparator
- Progression-free survival [ Time Frame: 12 months ]Survival period of patients in both arms of the study is measured in absence of tumor progression.
- Maintenance of body weight [ Time Frame: 3 and12 months ]Patient's body weight in kilograms measured at three month and at 12 month to assess possible disease related cachexia.
- Treatment emergent adverse effects [ Time Frame: 3 months ]Treatment-emergent adverse events including headache, bronchitis, dyspnea, cough, pyrexia, chest discomfort and liver function will be evaluated.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03472053
|Contact: Brian Dickson, MDemail@example.com|
|Contact: Indu Parikh, PhDfirstname.lastname@example.org|
|Vardhman Mahavir Medical College & Hospital||Recruiting|
|New Delhi, Delhi, India, 110029|
|Contact: Neeraj Singh, MS +91-880-048-8618 email@example.com|
|Principal Investigator: Satya P Kataria, MD|
|Sub-Investigator: Kaushal Kalra, MD|
|Sub-Investigator: Mukesh Nagar, MD|
|Aadhar Health Institute||Recruiting|
|Hisar, Hariyana, India, 125005|
|Contact: Harish Sharma, MD +91-989-653-9125 firstname.lastname@example.org|
|Contact: Coordinator +91-701-819-6594 email@example.com|
|Principal Investigator: Lovenish Goyal, MD|
|HCG Manavata Cancer Center||Recruiting|
|Nashik, Maharashtra, India, 422004|
|Contact: Nishtha Paleja, MBBS +91-982-325-8862 firstname.lastname@example.org|
|Principal Investigator: Rajnish Nagarkar, MSBSS|
|Sub-Investigator: Vijay Palwe, MD|
|Deenanath Mangeshkar Hospital & Research Center||Recruiting|
|Pune, Maharashtra, India, 411004|
|Contact: A Asmita, BS +91-996-008-4830 email@example.com|
|Principal Investigator: Chetan Deshmukh, MD|
|Sub-Investigator: Padmaj Kulkarni, MD|
|Tata Memorial Hospital||Recruiting|
|Mumbai, Maharastra, India, 400012|
|Contact: Vijay Patil, MD +91-986-938-2266 firstname.lastname@example.org|
|Contact: Coordinator +91-983-394-4571 email@example.com|
|Principal Investigator: Amit Joshi, MD|
|Sub-Investigator: Kumar Prabhash, MD|
|Chirayu Cancer Hospital||Recruiting|
|Bhopal, MP, India, 462030|
|Contact: Hakimudin Malvi, MD +91-942-567-2336 firstname.lastname@example.org|
|Principal Investigator: Tarini P Sahoo, MD|
|Sparsh Hospitals and Critical Care||Recruiting|
|Bhubaneswar, Odisa, India, 751007|
|Contact: Siddharth Mohanty, MS +91-732-707-8993 email@example.com|
|Principal Investigator: Ghanashyam Biswas, MD|
|Sub-Investigator: Bharat Das, MD|
|SMS Medical College & Hospital||Recruiting|
|Jaipur, Rajasthan, India, 302016|
|Contact: Shivraj Sharma, MD +91-141-400-7619 firstname.lastname@example.org|
|Contact: Coordinator +91-756-823-0335 email@example.com|
|Principal Investigator: Narendra Khippal, MD|
|Sub-Investigator: Shantanu Sharma, MD|
|Sub-Investigator: Sandeep Jasuja, MD|
|Nehru Hospital & Post Graduate Institute of Medical Education||Recruiting|
|Chandigarh, India, 160012|
|Contact: M Shashank, MS +91-988-805-8173 firstname.lastname@example.org|
|Principal Investigator: Navneet Singh, MD|
|Sub-Investigator: D Behra, MD|
|Sub-Investigator: R Kapoor, MD|
|Study Director:||Devesh Verma, PhD||Cliantha Research, India|